No changes in serum epidermal growth factor levels in patients with schizophrenia
No changes in serum epidermal growth factor levels in patients with schizophrenia
复制标题
DOI：
10.1016/j.psychres.2003.11.006
复制
发表时间：
2005-06-30
影响因子：
11.3
通讯作者：
Iyo, M
中科院分区：
文献类型：
--
作者：
Hashimoto, K;Shimizu, E;Iyo, M
最近的一份报告显示，精神分裂症患者血清中表皮生长因子（EGF）水平显著降低，提示EGF信号受损可能与精神分裂症的病理生理有关。我们本研究的目的是确定精神分裂症患者血清中EGF水平是否发生改变。我们发现，未接受药物治疗（n = 15）或接受药物治疗（n = 25）的精神分裂症患者血清EGF水平与年龄和性别匹配的正常对照（n = 40）没有差异。然而，我们发现联合组患者血清EGF水平与BPRS评分之间存在显著相关性。因此，我们的研究结果并不支持EGF在精神分裂症发病机制中发挥作用的说法，但它们表明EGF可能作为一种状态标志物，即作为症状相关缺陷的指标。2005爱思唯尔爱尔兰有限公司版权所有。
A recent report demonstrated that serum levels of epidermal growth factor (EGF) were significantly decreased in patients with schizophrenia, suggesting that impaired EGF signaling might be associated with the pathophysiology of schizophrenia. Our goal in the present study was to determine whether serum levels of EGF are altered in patients with schizophrenia. We found that serum levels of EGF in drug-naive (n = 15) or medicated patients (n = 25) with schizophrenia did not differ from those of age- and sex-matched normal controls (n = 40). However, we found a significant correlation between serum EGF levels and BPRS scores in the combined groups of patients. Therefore, our results do not support the claim that EGF plays a role in the pathogenesis of schizophrenia, but they suggest that EGF may serve as a state marker, that is, as an index of symptom-linked deficits. (C) 2005 Elsevier Ireland Ltd. All rights reserved.